Barclays’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Barclays’s Portfolio LABU Stock Details LABU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$83K	Sell	500 -5,100	-91%	-$837K	﹤0.01%	4104
2025 Q4	$893K	Buy	+5,600	New	+$769K	﹤0.01%	3512
2024 Q2	–	Sell	-136,900	Closed	-$18.2M	–	5112
2024 Q1	$18.2M	Sell	136,900 -14,715	-10%	-$1.92M	0.01%	1037
2023 Q4	$18.5M	Buy	+151,615	New	+$11.6M	0.01%	1097
2022 Q3	–	Sell	-65	Closed	-$9K	–	4983
2022 Q2	$9K	Hold	65	–	–	﹤0.01%	4666
2022 Q1	$20K	Buy	65 +55	+550%	+$20.7K	﹤0.01%	4442
2021 Q4	$7K	Buy	10 +6	+150%	+$5.74K	﹤0.01%	4013
2021 Q3	$4K	Buy	+4	New	+$4.92K	﹤0.01%	4624

Other funds holding LABU

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

MIG

McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return

Belvedere Trading Chicago, Illinois $84.4B AUM 52.68% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Barclays's LABU Position: Q1 2026 in Review

Barclays reduced its Direxion Daily S&P Biotech Bull 3X ETF (LABU) stake by 91% in Q1 2026, selling an estimated $837K and leaving 500 shares worth $83K. The position accounts for ﹤0.01% of the portfolio, ranked #4104.

Barclays first reported a position in LABU in Q3 2021 and has held it in 8 quarters since. The position peaked at $18.5M in Q4 2023. 33 funds tracked by Wall St. Rank hold LABU as of Q1 2026.

Barclays held 500 shares of Direxion Daily S&P Biotech Bull 3X ETF worth $83K as of Q1 2026.
Barclays sold 5,100 Direxion Daily S&P Biotech Bull 3X ETF shares in Q1 2026, an estimated $837K.
Direxion Daily S&P Biotech Bull 3X ETF made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4104 holding.
Barclays first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q3 2021 and has held it in 8 quarters since.
Barclays's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $18.5M in Q4 2023.
33 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.